PierianDx Closes up to $47.5 Million of Growth Capital
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"We are thrilled to work with OrbiMed and our existing investors as they share our vision for decentralized NGS testing that enables our laboratory and physician customers to better serve patients," states Mark McDonough, CEO of PierianDx. "This capital will allow us to continue building a world-class team and deliver transformative solutions to leading healthcare organizations everywhere so that they can bring genomics into their communities."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
ST. LOUIS -- Businesswire -- PierianDx, the global leader in clinical genomics knowledge, announced that it closed on $30 million of new growth capital including equity financing and a term loan facility, which includes access to additional tranches for up to $17.5 million by 2022 and 2023, subject to certain conditions. The financing was led by healthcare investment firm OrbiMed with existing investors Health Catalyst Capital, Research Triangle Institute, Inova Health Systems, ATW Partners, and SJF Ventures also participating. The new capital will drive commercial expansion in response to increased demand as more healthcare organizations seek to provide high quality, affordable, faster care locally to their patients by internalizing next generation sequencing (NGS) testing capabilities.
PierianDx partners directly with providers, laboratories, and medical centers of all sizes to build advanced NGS testing capabilities on site using its assay-agnostic, advanced interpretation technology and enabling services. Founded in 2014 as a technology transfer spinout from Washington University in St. Louis, PierianDx has established partnerships with industry leaders and medical facilities around the world as they build or expand upon their advanced precision medicine programs using NGS technology.
“To manifest the full impact of genomics, we must routinely apply it in clinical settings,” states Rakesh Nagarajan, Founder, President, and Chief Technical and Visionary Officer of PierianDx. “Our interpretation technology and services lead the way by empowering medical facilities to understand a patient’s genetic variation, identify the best treatment options, and deliver the most precise care.”
“We are thrilled to work with OrbiMed and our existing investors as they share our vision for decentralized NGS testing that enables our laboratory and physician customers to better serve patients,” states Mark McDonough, CEO of PierianDx. ”This capital will allow us to continue building a world-class team and deliver transformative solutions to leading healthcare organizations everywhere so that they can bring genomics into their communities.”
About PierianDx
PierianDx is a partner in precision medicine, enabling clinicians and medical facilities to advance clinical genomics programs and modernize patient care. We believe in the potential of genomics to transform human health, and are working to ensure that communities anywhere can experience the benefits. With advanced interpretation technology connected to the most comprehensive genomic knowledgebase, PierianDx empowers providers with genomic insights to fulfill the promise of precision care.
About OrbiMed
OrbiMed is a leading healthcare investment firm, with over $18 billion in assets under management. OrbiMed invests globally across the healthcare industry through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya and other key global markets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005411/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:PierianDx, Inc.
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- Alo Yoga, 방탄소년단 진 글로벌 앰배서더로 발탁… 한국 시장 확장 본격화 - 뉴스와이어
- 보조출연자-제작진 매칭 플랫폼 ‘왑’ 정식 오픈 - 뉴스와이어
- 현대자동차, 배터리 개발 기술인력 신규 채용 - 뉴스와이어
- 2024 아시아무용축전 ADF 서울, 10월 23일 대학로 마로니에 공원에서 개최 - 뉴스와이어
- 포스코인터내셔널, 주주친화정책과 디지털화를 선도하며 한국 IR대상 최우수상 수상 쾌거 - 뉴
- 메디데이터, 초기 및 후기 임상시험의 성장을 지원하는 레이브 라이트 솔루션 발표 - 뉴스와이어
- LG생활건강 에어 칫솔, 레드닷 ‘베스트 오브 베스트’ 선정 - 뉴스와이어
- 무자본 1인 출판사 창업과 수익화하기 특강 개최 - 뉴스와이어
- 북랩, 순간의 포착에 영원한 시간을 담은 그림 에세이 ‘나는 시간을 그린다 1·2’ 출간 - 뉴스와
- 삶과 죽음의 순환을 녹여낸 전시 ‘마인드붐 2024 : 발 아래 처음, 하늘 아래 마지막’ 성황리 개